Butalbital, Acetaminophen And Caffeine Capsule
NDC Package 51672-4222-1
Package Information
Butalbital, Acetaminophen And Caffeine capsules is butalbital, acetaminophen, and caffeine capsules are indicated for the relief of the symptom complex of tension (or muscle contraction) headache.Evidence supporting the efficacy and safety of this combination product in the treatment of multiple recurrent headaches is unavailable. This formulation utilizes a capsule delivery system. Marketed by Taro Pharmaceuticals U.s.a., Inc., this product is identified by NDC 51672-4222 and is authorized under FDA application ANDA213046.
Identification & Billing
- RxCUI: 889520 - butalbital 50 MG / acetaminophen 300 MG / caffeine 40 MG Oral Capsule
- RxCUI: 889520 - acetaminophen 300 MG / butalbital 50 MG / caffeine 40 MG Oral Capsule
- RxCUI: 889520 - APAP 300 MG / butalbital 50 MG / caffeine 40 MG Oral Capsule
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 51672 - Taro Pharmaceuticals U.s.a., Inc.
- 51672-4222 - Butalbital, Acetaminophen And Caffeine
- 51672-4222-1 - 100 CAPSULE in 1 BOTTLE
- 51672-4222 - Butalbital, Acetaminophen And Caffeine
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 51672-4222-1 identifies a specific commercial package of 100 capsule in 1 bottle of Butalbital, Acetaminophen And Caffeine, a human prescription drug labeled by Taro Pharmaceuticals U.s.a., Inc.. This capsule is formulated for oral use and contains acetaminophen; butalbital; caffeine as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Taro Pharmaceuticals U.s.a., Inc. on July 01, 2020. The current certification is valid through December 31, 2026.
How is this Taro Pharmaceuticals U.s.a., Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 51672422201. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.